Cash Flow Statement (Annual)

UVE / Universal Insurance Holdings, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities Continuing Operations
  Net Cash Provided By Used In Operating Activities Continuing Operations - - - 142,506 156,959 123,346 219,271 121,396 245,010
Net Cash Provided By Used In Investing Activities Continuing Operations
  Proceeds From Sale Of Other Property Plant And Equipment - - - 28 8 84 86 36 23
  Payments To Acquire Property Plant And Equipment 762 1,714 2,395 2,726 1,350 9,267 11,869 8,223 4,618
  Payments To Acquire Available For Sale Securities Equity 206,054 80,730 - - 77,859 116,541 65,038 66,688 89,302
  Payments To Acquire Available For Sale Securities Debt 325,674 129,141 - - 305,330 106,885 178,198 320,131 180,604
  Payments To Acquire Real Estate Held For Investment - - - - - - 6,220 5,496 7,218
  Proceeds From Sale Of Available For Sale Securities Equity 147,635 70,681 - - 15,542 163,981 41,456 60,558 77,640
  Proceeds From Sale Of Available For Sale Securities Debt 299,033 116,238 - - - 17,153 38,379 86,018 26,179
  Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities - - - - 16,306 24,287 74,390 54,615 97,191
  Net Cash Provided By Used In Investing Activities Continuing Operations - - - -2,698 -352,683 -77,188 -83,052 -174,311 -85,709
Net Cash Provided By Used In Financing Activities Continuing Operations
  Payments Of Dividends Preferred Stock And Preference Stock 27 20 20 287 29 13 10 10 10
  Payments Of Dividends Common Stock 20,313 12,533 12,750 18,669 17,725 19,240 22,287 24,192 24,001
  Payments For Repurchase Of Common Stock - - - - 32,366 29,736 18,649 8,510 18,141
  Payments Related To Tax Withholding For Share Based Compensation 223 4,292 172 121 3,161 17,655 12,141 5,451 7,223
  Repayments Of Debt 368 1,471 1,471 1,471 1,471 7,471 8,470 2,136 2,170
  Net Cash Provided By Used In Financing Activities Continuing Operations - - - -22,101 -34,393 -48,036 -54,602 -38,369 -51,545
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect - - - - - - - - -
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - -

Peers - Fire, Marine, and Casualty Insurance (6331)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 91359V107